文献速递心外重症与机械循环支持

EUROMACS注册研究:原发性双心室支持的结果分析

Results of primary biventricular support: an analysis of data from the EUROMACS registry.
PubMed 文献 · Eur J Cardiothorac Surg · 2019-01-01

本研究基于EUROMACS注册数据,描述2011至2017年间接受长期双心室辅助装置(BiVAD)、左心室辅助装置(LVAD)联合短期右心室辅助装置(RVAD)或全人工心脏(TAH)植入患者的适应症、生存率及并发症。共3282例中413例(12.5%)需双心室泵支持,各组1年生存率无统计学差异,但总体死亡率高。

要点

  • 连续流BiVAD、LVAD+短期RVAD、搏动性BiVAD和TAH的1年生存率分别为55%、52%、37%和36%,组间无统计学差异。
  • 超过50%的BiVAD支持患者为INTERMACS 1-2级,而INTERMACS 4-7级患者接受BiVAD植入的比例不足15%。
  • LVAD+短期RVAD支持3个月后,46.7%仍需持续支持,仅18.5%脱离RVAD,33.1%死亡。

核心结论

  • 双心室支持后死亡率高,但不同泵类型间生存率和不良事件无统计学差异。
  • 未来需结合生活质量和不良事件的复合终点以辅助机械循环支持的共同决策。

研究设计与样本

  • 共3282例患者中413例(12.5%)需要双心室泵,包括37例长期BiVAD、342例LVAD+短期RVAD和34例TAH。

主要发现

  • 连续流BiVAD的1年生存率为55%,LVAD+短期RVAD为52%,搏动性BiVAD为37%,TAH为36%。
  • 超过50%的BiVAD支持患者为INTERMACS 1和2级;INTERMACS 4-7级接受BiVAD植入者不足15%。
  • 搏动性BiVAD(n=15)和TAH(n=34)无一作为终点治疗植入,而连续流BiVAD有27%(n=6)、LVAD+短期RVAD有23%(n=342)作为终点治疗。
  • LVAD+短期RVAD支持3个月后,46.7%仍需持续支持,18.5%脱离RVAD,33.1%死亡。
  • 右心室每搏做功指数和右心衰竭评分提示所有组右室功能均差。

临床怎么用

  • 对于需要双心室支持的患者,连续流BiVAD或LVAD+短期RVAD的1年生存率相近,可作为选择参考。
  • 多数双心室支持患者为INTERMACS 1-2级,提示病情危重;终点治疗植入比例低,需谨慎评估适应症。

局限性

  • 原文未明确报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The purpose of this study was to describe pre- and postoperative data from the EUROMACS registry with regard to indications, for and survival and complication rates of patients with primary continuous flow and pulsatile biventricular long-term assist devices (BiVADs) versus total artificial hearts (TAHs) or left ventricular assist devices (LVADs) + short-term right ventricular assist device (RVAD) implants. METHODS: We investigated patients who received implants between 1 January 2011 and 21 October 2017. Clinical baseline information about comorbidities, laboratory results, medical and device therapies and echocardiographic, haemodynamic and right ventricle (RV) parameters were evaluated along with the rates of deaths and complications. RESULTS: A total of 413 of 3282 patients (12.5%) needed a biventricular pump. We investigated 37 long-term BiVADs, 342 LVAD + short-term RVAD implants and 34 TAHs. Minor differences were found in the baseline characteristics of our population, which had an overall high morbidity profile. The 1-year survival rate was 55% for patients with a continuous flow BiVAD; 52% for patients with an LVAD + short-term RVAD; 37% for patients with pulsatile BiVADs; and 36% for patients with a TAH. No statistical difference was observed among the groups. Over 50% of patients with BiVAD support were classified as INTERMACS profiles 1 and 2. The percent of patients with ambulatory heart failure (INTERMACS 4‒7) undergoing BiVAD implants was modest at <15%. No patients with a pulsatile BiVAD (n = 15) or a TAH (n = 34) were implanted as destination therapy, but 27% of the patients with continuous flow BiVADs (n = 6) and 23% of the patients with LVAD + short-term RVAD (n = 342) were implanted as 'destination'. The adverse events profile remained high, with no significant difference among pump types. The right ventricular stroke work index and right heart failure scores indicated poor RV function in all groups. After 3 months of LVAD + short-term RVAD support, 46.7% still required ongoing support, and only 18.5% were weaned from RVAD support; 33.1% died. CONCLUSIONS: The mortality rate after BiVAD support was high. Survival rates and adverse events were statistically not different among the investigated groups. In the future, composite study end points examining quality of life and adverse events beyond survival may help in shared decision-making prior to general mechanical circulatory support, particularly in patients with BiVAD implants.

来源:Eur J Cardiothorac Surg,查看原文。版权归原作者所有。

引用

  1. Vierecke J, Gahl B, de By TMMH, et al. Results of primary biventricular support: an analysis of data from the EUROMACS registry. Eur J Cardiothorac Surg. 2019. PMID: 31369075. doi:10.1093/ejcts/ezz173

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。